Journals / Balkan Medical Journal / 2020 / Cilt: 37 - Sayı: 6

The Diagnostic Value of sTWEAK in Acute Ischemic Stroke

Pages
336–340
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results were analyzed on SPSS 22.0 software (SPSS Inc., Chicago, IL, USA), and p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Considering the critical role of early diagnosis and management of acute ischemic stroke, biomarkers that can reliable assist in the diagnosis are still needed.
📊
Key Findings & Data:Soluble tumor necrosis factor-like weak inducer of apoptosis, a protein involved in the regulation of several biological functions, could be a potential acute ischemic stroke biomarker.Aims: To investigate the diagnostic value of soluble tumor necrosis factor-like weak inducer of apoptosis in patients with acute ischemic stroke and examine the relationship between ischemic area volume determined at diffusion-weighted magnetic resonance imaging and soluble tumor necrosis factor-like weak inducer of apoptosis.Study Design: A prospective, case-control study.Methods: This case-control prospective study included 36 patients with acute ischemic stroke and 36 healthy volunteers.
💡
Conclusion & Impact:The results were analyzed on SPSS 22.0 software (SPSS Inc., Chicago, IL, USA), and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Considering the critical role of early diagnosis and management of acute ischemic stroke, biomarkers that can reliable assist in the diagnosis are still needed. These biomarkers should rapidly analyze, have high specificity for brain damage, and be available in the emergency settings for early diagnosis and exclusion of other conditions that mimic acute ischemic stroke. Soluble tumor necrosis factor-like weak inducer of apoptosis, a protein involved in the regulation of several biological functions, could be a potential acute ischemic stroke biomarker.Aims: To investigate the diagnostic value of soluble tumor necrosis factor-like weak inducer of apoptosis in patients with acute ischemic stroke and examine the relationship between ischemic area volume determined at diffusion-weighted magnetic resonance imaging and soluble tumor necrosis factor-like weak inducer of apoptosis.Study Design: A prospective, case-control study.Methods: This case-control prospective study included 36 patients with acute ischemic stroke and 36 healthy volunteers. Information on age, sex, presence of chronic disease, neurological examination findings, times of presentation to the emergency department after acuteischemicstroke,solubletumornecrosisfactor-likeweakinducer of apoptosis levels, ischemic area volumes at diffusion-weighted magnetic resonance imaging, and 6-month mortality rates after stroke were recorded. The results were analyzed on SPSS 22.0 software (SPSS Inc., Chicago, IL, USA), and p

🔖

Cite This Article

BİLGİLİ, Y. K., COŞKUN, F., VURAL, S., BADEM, N. D., EROĞLU, O., COMERTPAY, E. (2022). The Diagnostic Value of sTWEAK in Acute Ischemic Stroke. Balkan Medical Journal, Cilt: 37 - Sayı: 6, 336–340. https://ajindex.com/articles/460895

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292
  2. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018;49:e46-99
  3. Musuka TD, Wilton SB, Traboulsi M, Hill MD. Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ 2015;187:887-93
  4. Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, et al. Diffusion-weighted MR imaging of acute stroke: correlation of T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR 1990;11:423-9
  5. Hjort N, Christensen S, Solling C, Ashkanian M, Wu O, Røhl L, et al. Ischemic injury detected by diffusion imaging 11 minutes after stroke. Ann Neurol 2005;58:462-5
  6. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16
  7. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-9
  8. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21
  9. Ortiz A, Sanchez-Nino M, Izquierdo M, Blanco-Colio LM, Selgas R, Ruiz-Ortega M, et al. TWEAK and the kidney: the dual role of a multifunctional cytokine. Adv Exp Med Biol 2011;691:323-35
  10. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010;85:681-90
  11. Inta I, Frauenknecht K, Dörr H, Kohlhof P, Rabsilber T, Auffarth GU, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci 2008;275:117-20
  12. Yilmaz MS, Yilmaz M, Isik B, Yel C, Kavalci C, Demirci B, et al. The correlation of TWEAK level and with involved area on MRI in stroke. Biomed Res 2017;28:1110-4
  13. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenth